Ubiquitin-dependent degradation of p73 is inhibited by PML.

p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev (2005) 3.02

The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J (2005) 2.38

Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat (2008) 1.32

The p53 circuit board. Biochim Biophys Acta (2012) 1.24

P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Oncogene (2011) 1.22

The Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch. Proc Natl Acad Sci U S A (2007) 1.19

PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation. Mol Cell Biol (2008) 1.17

High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy. Cell Death Dis (2014) 1.12

Regulation of p73 activity by post-translational modifications. Cell Death Dis (2012) 1.12

The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73. Oncogene (2009) 1.11

p73 expression is regulated by RNPC1, a target of the p53 family, via mRNA stability. Mol Cell Biol (2012) 1.10

Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2. Proc Natl Acad Sci U S A (2010) 1.08

Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase. Biochem J (2007) 1.07

Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia (2006) 1.05

Lysine-specific modifications of p53: a matter of life and death? Oncotarget (2013) 1.03

Kaposi's sarcoma-associated herpesvirus K-Rta exhibits SUMO-targeting ubiquitin ligase (STUbL) like activity and is essential for viral reactivation. PLoS Pathog (2013) 0.98

PML promotes MHC class II gene expression by stabilizing the class II transactivator. J Cell Biol (2012) 0.95

GCN5-dependent acetylation of HIV-1 integrase enhances viral integration. Retrovirology (2010) 0.93

Role of the promyelocytic leukaemia protein in cell death regulation. Cell Death Dis (2012) 0.90

Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73 abundance: mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs. Cell Death Differ (2014) 0.87

Cataloging and organizing p73 interactions in cell cycle arrest and apoptosis. Nucleic Acids Res (2008) 0.86

Some facts and thoughts: p73 as a tumor suppressor gene in the network of tumor suppressors. Mol Cancer (2007) 0.85

Cellular senescence and protein degradation: breaking down cancer. Cell Cycle (2014) 0.85

AMPK couples p73 with p53 in cell fate decision. Cell Death Differ (2014) 0.83

JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress. Cell Death Dis (2014) 0.81

Implication of TAp73 in the p53-independent pathway of Puma induction and Puma-dependent apoptosis in primary cortical neurons. J Neurochem (2010) 0.80

PML Surfs into HIPPO Tumor Suppressor Pathway. Front Oncol (2013) 0.80

Selection of novel mediators of E2F1-induced apoptosis through retroviral expression of an antisense cDNA library. Nucleic Acids Res (2005) 0.77

A novel dual signaling axis for NSP 5a3a induced apoptosis in head and neck carcinoma. Oncotarget (2011) 0.77

PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers. Oncogene (2009) 0.76

ΔNp73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype. Oncotarget (2016) 0.75

p73 gene in dopaminergic neurons is highly susceptible to manganese neurotoxicity. Neurotoxicology (2016) 0.75

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett (1997) 11.19

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (1995) 10.18

The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell (1991) 8.98

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33

Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature (2002) 7.71

Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell (1997) 7.27

p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature (2000) 5.83

p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature (1997) 5.42

Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell (1994) 5.37

The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (1999) 5.33

PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 4.90

p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56

Role of SUMO-1-modified PML in nuclear body formation. Blood (2000) 4.05

The transcriptional role of PML and the nuclear body. Nat Cell Biol (2000) 3.80

MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science (2002) 3.78

Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev (2001) 3.67

Chemosensitivity linked to p73 function. Cancer Cell (2003) 3.63

On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet (2002) 3.57

p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature (1999) 3.55

Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (1999) 3.50

Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem (2002) 3.37

PML is induced by oncogenic ras and promotes premature senescence. Genes Dev (2000) 3.35

p73: Friend or foe in tumorigenesis. Nat Rev Cancer (2002) 3.30

MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J (2002) 3.29

The role of PML in tumor suppression. Cell (2002) 3.28

Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem (2000) 3.01

Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene (1991) 2.86

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65

Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell (2003) 2.54

Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ (2001) 2.40

Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med (1998) 2.40

Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J (2000) 2.38

DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell (2002) 2.29

The function of PML in p53-dependent apoptosis. Nat Cell Biol (2000) 2.24

Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell (2002) 2.18

Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ (2002) 2.14

A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature (2000) 2.10

14-3-3 proteins block apoptosis and differentially regulate MAPK cascades. EMBO J (2000) 2.06

A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene (2000) 1.85

An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep (2002) 1.71

Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. Cancer Res (1999) 1.69

Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med (2001) 1.63

Mdm2 binds p73 alpha without targeting degradation. Oncogene (1999) 1.62

Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci U S A (2003) 1.47

CREB-binding protein (CBP)/p300 and RNA polymerase II colocalize in transcriptionally active domains in the nucleus. J Cell Biol (2000) 1.41

Promoter specificity and stability control of the p53-related protein p73. Oncogene (1999) 1.36

Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J Biol Chem (2000) 1.35

Oncogenes induce and activate endogenous p73 protein. J Biol Chem (2000) 1.34

PML colocalizes with and stabilizes the DNA damage response protein TopBP1. Mol Cell Biol (2003) 1.29

MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr Biol (1999) 1.24

PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res (2003) 1.19

Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene (2002) 1.19

Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J (2004) 1.16

The theory of APL. Oncogene (2001) 1.12

Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor co-activator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential. J Biol Chem (2003) 1.11

The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem (2003) 1.11

Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochem Biophys Res Commun (2000) 0.92

p53 De-ubiquitination: at the edge between life and death. Nat Cell Biol (2002) 0.76

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83

A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 13.82

Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature (2002) 10.96

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74

A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell (2011) 10.50

Tenets of PTEN tumor suppression. Cell (2008) 8.61

The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol (2004) 8.21

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75

Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62

The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26

Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell (2011) 7.02

Does the ribosome translate cancer? Nat Rev Cancer (2003) 6.89

Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52

The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol (2005) 6.27

Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer (2008) 6.10

S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science (2006) 5.94

Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol (2007) 5.79

Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62

Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet (2004) 5.55

NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20

In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell (2011) 5.19

The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01

Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88

TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev (2008) 4.85

Nucleophosmin and cancer. Nat Rev Cancer (2006) 4.82

Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev (2004) 4.68

Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell (2011) 4.49

Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30

Subtle variations in Pten dose determine cancer susceptibility. Nat Genet (2010) 4.19

The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol (2008) 4.15

Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 4.15

Role of nucleophosmin in embryonic development and tumorigenesis. Nature (2005) 4.09

The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell (2008) 4.04

The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell (2005) 3.96

SUMO modification of Huntingtin and Huntington's disease pathology. Science (2004) 3.85

Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development (2004) 3.75

Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature (2005) 3.75

PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 3.75

Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature (2004) 3.73

SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell (2011) 3.71

Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68

Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem (2003) 3.68

Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell (2003) 3.62

SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science (2007) 3.59

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest (2009) 3.55

Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature (2003) 3.54

The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature (2008) 3.53

PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev (2008) 3.50

PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex. Genes Dev (2008) 3.49

A continuum model for tumour suppression. Nature (2011) 3.48

A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest (2010) 3.47

Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest (2002) 3.36

The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell (2008) 3.35

A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med (2012) 3.33

Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth. Nature (2006) 3.31

The role of PML in tumor suppression. Cell (2002) 3.28

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24

Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest (2009) 3.23

The mechanisms of PML-nuclear body formation. Mol Cell (2006) 3.22

PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science (2010) 3.21

Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science (2003) 3.18

Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst (2004) 3.17

eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13

Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the efficient clearance of dead cells. Proc Natl Acad Sci U S A (2011) 3.11

Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09

The after-hours mutant reveals a role for Fbxl3 in determining mammalian circadian period. Science (2007) 3.05

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02

American Idol and NIH Grant Review. Cell (2006) 3.01

PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature (2006) 3.01

Generation of functional multipotent adult stem cells from GPR125+ germline progenitors. Nature (2007) 3.01

Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol (2009) 2.97

A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 2.95

Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science (2007) 2.92

Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol (2009) 2.91

Cytoplasmic PML function in TGF-beta signalling. Nature (2004) 2.89

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med (2008) 2.85

The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev (2006) 2.76

Pro-senescence therapy for cancer treatment. Nat Rev Cancer (2011) 2.75

SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol Cell (2006) 2.75

Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol Cell (2005) 2.75

PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 2.66

Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer (2013) 2.59

Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol (2013) 2.56

Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell (2003) 2.54

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov (2012) 2.53

Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell (2003) 2.53

A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res (2006) 2.50

Control of chromosome stability by the beta-TrCP-REST-Mad2 axis. Nature (2008) 2.46

PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol (2004) 2.45

PML is a direct p53 target that modulates p53 effector functions. Mol Cell (2004) 2.40

Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell (2012) 2.39

The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J (2005) 2.38

Caspase 8 inhibits programmed necrosis by processing CYLD. Nat Cell Biol (2011) 2.37

APC/C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol Cell (2007) 2.35

Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol (2012) 2.34

The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell (2013) 2.33

Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J Virol (2003) 2.33